Johnson & Johnson exec Dr Sarah ... combined with data on “cannabidiol”, a product derived from medicinal cannabis to determine if the existing drugs could be enhanced by combining them ...

Three of the largest drug distributors in the US, alongside drug-making company Johnson & Johnson, agreed to pay approximately $590 million dollars to Native American tribes that claim the ...

Johnson & Johnson’s rebate model aims to address misuse of 340B Program. HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes.

On Friday, Johnson & Johnson (NYSE:JNJ) announced that it would implement significant changes to offering 340B pricing for ...

When Johnson & Johnson backed down from its proposal to modify the way it supplies certain drugs under the 340B statute, it hinted litigation could be its next step to effect changes that address ...

Johnson & Johnson exec Dr Sarah Siggins has signed on for ASX-listed Algorae Pharmaceuticals’ hunt to create drug ...

US drugs giant Johnson & Johnson is to pay $230m (£165m) to settle claims it fuelled an opioid addiction crisis in New York State. The firm did not admit liability or wrongdoing in settling with ...

Johnson and Johnson revealed lower earnings and sales numbers than expected in Q4 2022 Even before Q4 numbers were released, JNJ started falling after a slew of new stories hit the press Even ...

In my estimation, the second most significant drug in Johnson & Johnson's oncology franchise ... and potential approvals of its product candidates including nipocalimab, JNJ-4804, and TAR-200.